Tests patient's own insulin-producing stem cells for type 1 diabetes in youth
Tests infusion of insulin-producing stem cells in young people with type 1 diabetes.
Plain-language title generated from the registry record
Registry title: Insulin Producing Stem Cell Transplantation Clinical Trial in Type 1 Diabetes
Key facts
- Where
- Cairo, EgyptSee the site
- Phase
- Phase 2/3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 15 and 18 years old?
Source: NCT06951074, who can take part
Where in Egypt
- Children Hospital EldemerdashCairo, EgyptTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ain Shams University
- Trial code
- NCT06951074
- Record updated
- 30 April 2025
- Original description
Type 1 Diabetes is a chronic autoimmune disease. It results from autoimmune destruction of pancreatic Beta cells leading to absolute insulin insufficiency. The establishment of pluripotent like human stem cells derived from adipose tissue derived mesenchymal cell origin have introduced a new potential source for cell therapy in type 1 diabetic patients, especially in light of recent successes in producing glucose-sensitive insulin secreting cells and this will be the scope of this study. In the last decade, human clinical trials of introducing insulin producing stem cells from various origins were approved and conducted.Read full original descriptionShow less
Autologous Insulin Producing Mesenchymal Stem Cell Transplantation in Youth With Type 1 Diabetes
Type 1 Diabetes is a chronic autoimmune disease. It results from autoimmune destruction of pancreatic Beta cells leading to absolute insulin insufficiency. The establishment of pluripotent like human stem cells derived from adipose tissue derived mesenchymal cell origin have introduced a new potential source for cell therapy in type 1 diabetic patients, especially in light of recent successes in producing glucose-sensitive insulin secreting cells and this will be the scope of this study. In the last decade, human clinical trials of introducing insulin producing stem cells from various origins were approved and conducted.
Inclusion: Type 1 diabetes.
Exclusion: patients with other autoimmune diseases; patients with other chronic diseases; patients with micro or macro vascular complications.